Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 7OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Breast Cancer Metastatic 1Acrocephalosyndactylia 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Rogaratinib × Clear all
NCT04483505 2023-12-28

ROGABREAST

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1 Completed
9 enrolled
BreastOther neoplasm

Breast Cancer Metastatic

NCT03762122 2022-11-09

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Swiss Cancer Institute

Phase 2 Terminated
15 enrolled

Acrocephalosyndactylia

NCT04040725 2019-12-17

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡